Application of naringenin and naringin in tumor radiotherapy
US10307393B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 25, 2016 |
| Grant date | Jun 4, 2019 |
| Priority date | — |
| Expiry date | Aug 25, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N5/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides applications of a small molecular flavonoid compound in preparing a medication for sensitizing/synergizing tumor radiation therapy as well as reducing radioactive damage. The small molecular flavonoid compound can be naringenin, hesperetin, luteolin and apigenin, etc. The medication contains a small molecular flavonoid compound and a plurality of conventional pharmaceutical additives; wherein the small molecular flavonoid compound is an active ingredient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.